Utility of Clinical Risk Stratification in the Selection of Muscle-Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy: A Retrospective Cohort Study

Introduction: Level I evidence supports the use of cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer prior to radical cystectomy (RC). On average, 30–40% of patients achieve a complete pathologic response (i.e., stage pT0) after receiving NAC. Some centers risk-strati...

Descripción completa

Detalles Bibliográficos
Autores principales: von Rundstedt, Friedrich-Carl, Mata, Douglas A., Kryvenko, Oleksandr N., Shah, Anup A., Jhun, Iny, Lerner, Seth P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2017
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5271426/
https://www.ncbi.nlm.nih.gov/pubmed/28149933
http://dx.doi.org/10.3233/BLC-160062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5271426/
https://www.ncbi.nlm.nih.gov/pubmed/28149933
http://dx.doi.org/10.3233/BLC-160062

Ejemplares similares